摘要:
The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophageal reflux.
摘要:
The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophageal reflux.
摘要:
The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents preferably selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.
摘要:
The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.
摘要:
The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. Said invention can be used for curing digestive pathologies.
摘要:
The present invention relates to S-tenatoprazole monohydrated sodium salt, represented by the following formula and the use thereof in therapy for the treatment of digestive diseases.
摘要:
The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. The enantiomer (−) of tentoprazole can be used for treating digestive pathologies.
摘要:
The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. The enantiomer (−) of tentoprazole can be used for treating digestive pathologies.
摘要:
The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfonyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. Said invention can be used for curing digestive pathologies.
摘要:
The invention concerns novel flavone and isoflavone derivatives of formulae (Ia) and (Ib) wherein: X represents a group of formula —COOR, or —PO(OR)2; R represents a hydrogen atom or an alkaline or alkaline-earth metal, or a lower alkyl group; R1 represents a hydroxy group, a lower alkoxy group or an acyloxy group; R2 and R3, identical or different, represent a hydrogen or halogen atom, or a trifluoromethyl group, a trichloromethyl group, a hydroxy group, an alkoxy group or an acyloxy group comprising 1 to 5 carbon atoms, or R2 and R3 can combine to form an alkylene dioxy group. The invention is useful for rheumatic diseases.
摘要翻译:本发明涉及式(Ia)和(Ib)的新型黄酮和异黄酮衍生物,其中:X代表式-COOR或-PO(OR)2的基团; R表示氢原子或碱金属或碱土金属或低级烷基; R 1表示羟基,低级烷氧基或酰氧基; R 2和R 3相同或不同,表示氢或卤素原子,或三氟甲基,三氯甲基,羟基,烷氧基或酰氧基 包含1至5个碳原子的基团或R 2和R 3可以结合形成亚烷基二氧基。 本发明可用于风湿性疾病。